Clinical trials: Human Papillomavirus Vaccines
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Vaccine Refusal, Vaccine Hesitancy
Active Health Education to Increase HPV Vaccine Coverage in Youth: A Stepped-wedge, Cluster, and Randomized Trial
This study aims to evaluate the impact of active health education methodologies on increasing adherence to the HPV vaccine among schoolchildren.
- Trial name
- EDUCAVAC (NCT06513494)
- Testing
- Active Students Education plus Teacher Training, Active Students Education, Basic Health Unit Active Orientation
- Where
- 79 sites in Brazil
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Hospital Israelita Albert Einstein
Human Papilloma Virus, Anal Dysplasia
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen…
- Conditions
- Human Papilloma Virus, Anal Dysplasia, HIV
- Trial name
- PROTECT (NCT06624839)
- Testing
- Human papillomavirus (HPV) vaccine, 9-valent
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HPV
HPV Vaccine Reduced Dose
This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone…
- Trial name
- NCT06799494
- Testing
- Gardasil-9, Lidocaine injection, Lorazepam
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Emory University
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Infections, Papillomavirus
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
This is a multicenter study in which women are planned to receive either the HPV vaccine or control. Study participation will last approximately 72 months and involves a total of thirteen or fourteen scheduled visits.
- Trial name
- NCT00779766
- Testing
- HPV GSK 580299 vaccine
- Where
- 4 sites in China
- Volunteers
- 6,081 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Diseases, Kidney Transplant
Immunogenicity of HPV Vaccine in Transplant Recipients.
To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.
- Trial name
- NCT05557370
- Testing
- Human Papilloma Virus vaccine (GARDASIL 9)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Human Papilloma Virus Vaccine Hesitancy
HPV Vaccine Hesitancy Among Indiana Youth With Cancer and Blood Diseases
For the identified groups of patients (survivors of childhood cancer and youth with sickle cell disease) the investigators want to better understand the barriers to, and facilitators of, HPV vaccination.
- Trial name
- NCT04667702
- Testing
- Interviews
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Indiana University
Human Papillomavirus Vaccines
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial
HPV vaccine coverage among adolescents in the US is suboptimal. This is particularly true among traditionally underserved adolescents. Few parent-targeted interventions have focused on the parental decision-making process.
- Trial name
- NCT02535845
- Testing
- Project Voice, HPV Informational Video
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
HPV Vaccine
Impact of a Mock-up Fact-checking Extension on HPV Vaccine Misinformation: A Survey Experiment
The primary objective of this survey experiment study is to measure the impact of a mock-up Chinese fact-checking extension on the ability to dispel HPV and HPV vaccine-related misinformation among parents of middle school girls…
- Trial name
- NCT06405048
- Testing
- Mobile Weibo post screenshot with mock-up Chinese fact-checking extension
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Fudan University
Condylomata Acuminata, Cervical Cancer
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase II clinical study was designed to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter called HPV vaccine), manufactured by Xiamen…
- Trial name
- NCT03935204
- Testing
- HPV Vaccine,270μg/1.0ml
- Where
- China
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Infections, Papillomavirus
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e.
- Trial name
- NCT01905462
- Testing
- Data Collection, Cervarix
- Where
- United Kingdom
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Papillomavirus Infections
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
This is a 96-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT04708041
- Testing
- 9vHPV vaccine
- Where
- 30 sites in United States, Colombia and 4 more
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Menstrual Disorder, Premature Ovarian Failure
The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
Cervical cancer is one of the most common cancer in women, making it the fourth largest cause of female cancer mortality worldwide.
- Trial name
- NCT05838157
- Testing
- prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
HPV Infection
HPV Vaccine in Postpartum Women
The purpose of this study is to determine the acceptability of HPV vaccination in postpartum women in Central Pennsylvania. Participants will be recruited while inpatient in the postpartum unit.
- Trial name
- NCT04430907
- Testing
- HPV 9-valent Vaccine, Recombinant
- Volunteers
- healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00849381
- Testing
- GSK580299, GSK Biological's HPV vaccine
- Where
- 9 sites in Brazil, Taiwan and 1 more
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer. PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well…
- Conditions
- Cervical Cancer, Nonneoplastic Condition, Precancerous Condition
- Trial name
- NCT00667563
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, DNA analysis, polymerase chain reaction
- Where
- India
- Volunteers
- 150 people
- Sponsor
- AIDS Malignancy Consortium
Human Papillomavirus Infection
Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine
This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).
- Trial name
- NCT01702337
- Testing
- Prevalence-based model
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neoplasia
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia
The researchers involved in this new study are interested in whether giving a HPV vaccine to women at the same time as conisation can lead to a greater rate of HPV clearance compared to conisation on its own, and a result reduce…
- Trial name
- NOVEL (NCT03979014)
- Testing
- Gardasill 9™ vaccine
- Where
- 13 sites in Finland, Sweden and 1 more
- Volunteers
- 1,099 people
- Sponsor
- Imperial College London
HPV Vaccine
Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students
Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program.
- Trial name
- CIRN-HPV-ONE (NCT07156084)
- Testing
- HPV nonavalent vaccine (Gardasil-9)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network